GUAN CHAO HLDGS has entered into three final agreements, including a trademark licensing agreement; an exclusive authorization agreement with Li Zi; and an exclusive authorization agreement with Jing Tai

According to the announcement from Guan Chao Holdings (01872), on May 26, 2025, the company's wholly-owned subsidiary BetaMind Investments Limited (BetaMind) entered into three final agreements, including a trademark licensing agreement; an exclusive authorization agreement with Li Zi; and an exclusive authorization agreement with Jing Tai.

On May 26, 2025, BetaMind signed a trademark licensing agreement (the "Trademark Licensing Agreement") with Shenzhen Li Zi Rui Ya. This agreement grants BetaMind and its designated contacts the right to use the target trademark (i.e., trademarks related to the "Groland" brand). According to the terms of the Trademark Licensing Agreement, the license for the target trademark is valid for twelve months from the effective date of the Trademark Licensing Agreement, depending on whether BetaMind pays the initial licensing fee stipulated in the Trademark Licensing Agreement. The licensed area for the target trademark includes the countries or regions where the target trademark is registered.

On the same day, BetaMind, Shenzhen Li Zi Rui Ya, and Shenzhen Jing Tai signed an exclusive authorization agreement (the "Li Zi Exclusive Authorization Agreement"). This agreement stipulates that Shenzhen Jing Tai and its affiliates (i.e., Shenzhen Zhong Ge Biotechnology Co., Ltd. (Shenzhen Zhong Ge)) will grant BetaMind exclusive rights (including sublicensing rights) to partially use the target compound XTP-016 in the global application of the cyclic peptide compound CN202311247312.8 (the "XTP-016 License"). The Li Zi Exclusive Authorization Agreement is valid for twelve months from the date of signing. During this period, BetaMind is authorized to engage in research, development, improvement, manufacturing, use, commercialization, sale, offer for sale, export, and import of the target compound XTP-016 and/or related products.

In addition to the above, on May 26, 2025, BetaMind signed an exclusive authorization agreement (the "Jing Tai Exclusive Authorization Agreement") with Shenzhen Jing Tai. This agreement stipulates that Shenzhen Jing Tai and its affiliates (i.e., Shenzhen Zhong Ge) will grant BetaMind exclusive rights (including sublicensing rights) to partially use the amino acid carbamate compounds and their derivatives and applications with the cyclic peptide compound CN202311128222.7 in the target compound XTP-018 (the "XTP-018 License"). The Jing Tai Exclusive Authorization Agreement is valid for twelve months from the date of signing. During this period, BetaMind is authorized to engage in research, development, improvement, manufacturing, use, commercialization, sale, offer for sale, export, and import of the target compound XTP-018 and/or related products.

The announcement disclosed that the XTP-016 License and XTP-018 License include proprietary technologies and key raw materials that are crucial for formulating hair growth products. These materials serve as the main active ingredients in research and development work. According to the information available to the directors, the compound XTP-018 related to the XTP-018 License is intended for the development and production of second-generation products, while the compound XTP-016 mentioned in the XTP-016 License is designated for the development and production of first-generation products After comprehensive due diligence and strategic business planning, the board believes that entering into such agreements presents valuable opportunities for the Group. These transactions are considered an appropriate way to leverage the relevant value of the target trademarks, XTP-016 licensing rights, and XTP-018 licensing rights. This move will allow the Group to enter promising new business areas, supported by a well-structured business model that integrates artificial intelligence and robotics research and development frameworks, covering production, sales, and distribution planning. Currently, the board is formulating a budget for additional investments aimed at establishing the new business. The proposed budget will cover various key areas, including human resources, production facilities, necessary equipment, sales and marketing plans, promotional activities, contact work, logistics, and raw material procurement.

The board is confident that, in the long run, this new business initiative will enhance the Group's sustainable growth capacity and broaden its revenue sources. Therefore, this move is seen as being in the overall best interests of the Company and its shareholders